[ad_1]
New Delhi:
Sun Pharmaceutical Industries has mentioned it has launched Favipiravir (200 mg) in India underneath the model FluGuard at a cheap value of Rs 35 per pill for the therapy of gentle to reasonable instances of COVID-19.
Favipiravir is the one oral anti-viral therapy authorised within the nation for the potential therapy of sufferers with gentle to reasonable COVID-19 illness.
With over 50,000 COVID-19 instances being reported each day in India, there’s an pressing want to offer extra therapy choices to healthcare professionals, mentioned Kirti Ganorkar, CEO of India Business at Sun Pharma.
“We are launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This is in line with our continuous efforts to support India”s pandemic response,” he mentioned in an announcement.
The firm will work intently with the federal government and medical group to make sure the supply of FluGuard to sufferers throughout the nation. The shares of FluGuard will probably be out there available in the market this week.
Sun Pharma is the world’s fourth-largest speciality generic pharmaceutical firm and India’s prime pharmaceutical firm.
Delivering merchandise for patrons and sufferers in over 100 nations, its world presence is supported by manufacturing amenities unfold throughout six continents that are authorised by a number of regulatory businesses.
[ad_2]
Source hyperlink